Victor Rivera - Theseus Pharmaceuticals VP CoFounder

THRXDelisted Stock  USD 3.71  0.14  3.92%   

Insider

Victor Rivera is VP CoFounder of Theseus Pharmaceuticals
Age 60
Phone857 400 9491
Webhttps://theseusrx.com

Theseus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Theseus Pharmaceuticals currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Senthil SundaramTerns Pharmaceuticals
46
Marine PopoffHookipa Pharma
N/A
Leah NeufeldImmuneering Corp
51
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Filip MDMonte Rosa Therapeutics
50
Deepika PharmDPmv Pharmaceuticals
47
David MackPmv Pharmaceuticals
62
Jason BarkerArcus Biosciences
49
Murray MDX4 Pharmaceuticals
63
Winston MBAPmv Pharmaceuticals
48
Andreas BergthalerHookipa Pharma
N/A
Anna MBAMersana Therapeutics
60
Lukas FlatzHookipa Pharma
N/A
Aseem AnsariDesign Therapeutics
N/A
Wei MDErasca Inc
54
Mary DiBiaseX4 Pharmaceuticals
63
MBA MDCullinan Oncology LLC
51
Joo MDDesign Therapeutics
61
Robert IIArcus Biosciences
51
Kerry WhalenCullinan Oncology LLC
N/A
Peter KingImmuneering Corp
N/A
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Theseus Pharmaceuticals (THRX) is traded on NASDAQ Exchange in USA and employs 38 people.

Management Performance

Theseus Pharmaceuticals Leadership Team

Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
DPhil DPHIL, CoFounder Chairman
Timothy Clackson, Pres CEO
Len Rozamus, VP Operations
Nachu Narasimhan, VP Safety
Bradford Dahms, Chief officer
WeiSheng Huang, CoFounder Chemistry
Alicja Januszewicz, VP Culture
Victor Rivera, VP CoFounder
Benjamin Enerson, VP Affairs
Kristine CPA, VP Controller
MA DPHIL, CoFounder Chairman
David MD, Chief Officer
William Shakespeare, CoFounder RD

Theseus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Theseus Stock

If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamental Analysis
View fundamental data based on most recent published financial statements